<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="262">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157737</url>
  </required_header>
  <id_info>
    <org_study_id>2020-520</org_study_id>
    <nct_id>NCT05157737</nct_id>
  </id_info>
  <brief_title>Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy</brief_title>
  <official_title>Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of study on KCNQ2-related epilepsy: (1) establish phenotype database and sample&#xD;
      database of KCNQ2-related epilepsy; (2) to establish genotype-phenotype association of&#xD;
      KCNQ2-related epilepsy; (3) to study the brain network of KCNQ2-related epilepsy based on&#xD;
      multi-modal brain image and EEG data; (4) to find prognostic biomarkers of KCNQ2-related&#xD;
      epilepsy based on omics study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Participant recruitment: participants are recruited from Chinese KCNQ2-related epilepsy&#xD;
           patients group (http://www.kcnq2.cn/). According to the clinical phenotype, the&#xD;
           participants will be divided into benign familial neonatal seizures (BFNS) group and&#xD;
           Developmental and epileptic encephalopathy (DEE) group.&#xD;
&#xD;
        2. Genotype-phenotype association: electrophysiological detection of KCNQ2 mutation will be&#xD;
           performed using patch clamp technique in an in vitro cell model. The association between&#xD;
           phenotype (such as epileptic phenotype, developmental assessment and drug response) and&#xD;
           genotype will be analyzed.&#xD;
&#xD;
        3. Brain network analysis: participants who provide informed consent will be scaned by&#xD;
           brain magnetic resonance imaging (MRI) or positron emission tomography-computed&#xD;
           tomography (PET-CT) and monitored by the electroencephalogram (EEG). The Brain Network&#xD;
           of KCNQ2-related epilepsy will be analyzed based on multi-modal brain image and EEG&#xD;
           between BFNS and DEE group.&#xD;
&#xD;
        4. Omics Study: after informed consent, blood, urine and feces samples of participants will&#xD;
           be taken. The samples were tested for omics study including proteomics, metabolomics,&#xD;
           transcriptomics, to analysis the difference of BFNS and DEE group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Establish the phenotype database and genotype-phenotype association of KCNQ2-related Epilepsy</measure>
    <time_frame>0-18 years old</time_frame>
    <description>Analysis of Clinical information of KCNQ2-related Epilepsy such as phenotype, genotype, brain image ,EEG, living quality and comorbidity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study on the brain network of KCNQ2-related epilepsy</measure>
    <time_frame>0-18 years old</time_frame>
    <description>Analysis of brain network of KCNQ2-related epilepsy based on multi-modal brain image and EEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study on the omics testing of KCNQ2-related epilepsy</measure>
    <time_frame>0-18 years old</time_frame>
    <description>Analysis of prognostic biomarker of KCNQ2-related epilepsy based on proteomics, metabolomics, transcriptomics.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>KCNQ2-related Epilepsy</condition>
  <arm_group>
    <arm_group_label>BFNS group</arm_group_label>
    <description>(1) Epileptic seizure in neonatal period; (2) Epileptic seizure duration is short, which under spontaneous control in 4~6 months; (3) The patient was in normal state of feeding, physical examination and psychomotor development; (4) There were no signs of hypsarrhythmia or burst suppression in EEG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEE group</arm_group_label>
    <description>(1) Epileptic seizures occur within a week after birth and recur frequently; (2) Epilepsy is refractory; (3) Feeding difficulties, accompanied by moderate to severe mental retardation and psychomotor retardation; (4) The EEG showed hypsarrhythmia or burst suppression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrophysiological detection of KCNQ2 mutation</intervention_name>
    <description>Electrophysiological detection of KCNQ2 mutation performed using patch clamp technique in an in vitro cell model. Analyze the association between phenotype and genotype.</description>
    <arm_group_label>BFNS group</arm_group_label>
    <arm_group_label>DEE group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multi-modal brain image and EEG</intervention_name>
    <description>Multi-modal brain image include brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). The electroencephalogram (EEG) incuding video electroencephalogram (VEEG) and sleep electroencephalogram (SEEG).</description>
    <arm_group_label>BFNS group</arm_group_label>
    <arm_group_label>DEE group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Omics testing</intervention_name>
    <description>Omics testing include proteomics, metabolomics, transcriptomics.</description>
    <arm_group_label>BFNS group</arm_group_label>
    <arm_group_label>DEE group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biospecimen include whole blood 4ml (isolate plasma and blood cells), urine 15ml, feces 3-5g.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients of KCNQ2-related epilepsy who meet the clinical and genetic diagnosis&#xD;
        criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  KCNQ2 mutation was confirmed by WES, Panel and other gene tests;&#xD;
&#xD;
          -  Clinically diagnosed as epilepsy;&#xD;
&#xD;
          -  KCNQ2 mutation was identified as pathogenic or possibly pathogenic according to ACMG&#xD;
             pathogenicity rating standard;&#xD;
&#xD;
          -  Age and gender are not limited;&#xD;
&#xD;
          -  No abnormal birth history;&#xD;
&#xD;
          -  Informed consent and willingness to follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with KCNQ2 mutation without epilepsy;&#xD;
&#xD;
          -  Other possible pathogenic gene mutations except KCNQ2;&#xD;
&#xD;
          -  Large cross-gene deletions or duplications including KCNQ2;&#xD;
&#xD;
          -  Unable to participate in the study follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Wang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Wang, Dr</last_name>
    <phone>13564766228</phone>
    <email>yiwang@shmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200232</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Wang, Dr.</last_name>
      <phone>+8613564766228</phone>
      <email>yiwang@shmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Yi Wang</investigator_full_name>
    <investigator_title>Professer</investigator_title>
  </responsible_party>
  <keyword>KCNQ2-related epilepsy</keyword>
  <keyword>Benign familial neonatal seizures</keyword>
  <keyword>Developmental and epileptic encephalopathy</keyword>
  <keyword>Genotype-phenotype association</keyword>
  <keyword>Brain network</keyword>
  <keyword>Omics study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

